#Germany #Biomarkers #Critical Care #SphingoTec #Hennigsdorf

SphingoTec's Active Participation in Major Conferences

SphingoTec GmbH, a prominent name in the field of biomarkers, is excited to announce its participation in a series of major conferences scheduled for 2026. These conferences will cover topics related to diagnostics and critical care medicine, highlighting the company's ongoing commitment to advancing biomarker-driven solutions. By presenting at these events, SphingoTec aims to support earlier and more precise clinical decision-making in acute care settings.

Upcoming Conference Schedule

The company's conference lineup for the next few months includes:

• - DGAI (German Society of Anesthesiology and Intensive Care Medicine)

September 16-18, 2026, in Kassel, Germany.

• - Congress for Nephrology 2026 (DGFN / German Society of Nephrology)

October 8-11, 2026, in Leipzig, Germany.

• - ESICM Lives

October 10-14, 2026, in Lisbon, Portugal. SphingoTec will co-host a Scientific Symposium in collaboration with business partner Boditech that focuses on innovations in sepsis diagnostics. During this event, new clinical data regarding penKid from a multicenter sepsis study will be showcased in poster format.

• - ASN Kidney Week 2026

October 22-25, 2026, in Denver, CO, USA. At this important gathering, penKid will be featured prominently during the poster sessions, accompanied by the abstract, "Proenkephalin Predicts Severe AKI in High-Risk Patients."

• - Medica

November 16-19, 2026, in Düsseldorf, Germany. This event will emphasize SphingoTec's mission to expand its international industry network and explore partnership opportunities for its biomarker portfolio.

• - DIVI (German Interdisciplinary Association for Intensive Care and Emergency Medicine)

December 2-4, 2026, in Hamburg, Germany.

Deborah Bergmann, the CEO of SphingoTec, stated, "These events bring together clinicians, researchers, and industry partners who share our goal of improving outcomes for patients in critical care. By presenting our latest data and engaging in direct dialogue, we aim to strengthen collaborations that translate biomarker innovation into real clinical value."

About SphingoTec

SphingoTec GmbH, located in Hennigsdorf, near Berlin, Germany, is a biomarker company dedicated to developing innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. Their primary focus is on out-licensing these biomarkers, which are designed to be commercialized across various IVD platforms. Notably, SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), used for assessing kidney function in critical illnesses, and bioactive Adrenomedullin 1-52 (bio-ADM), which assesses endothelial function in acute heart failure conditions. For further information, visit www.sphingotec.com.

By actively engaging in these upcoming conferences, SphingoTec emphasizes its dedication to advancing clinical practices through biomarker innovation.